Genetic testing for plasma cell disorders
Part of Cancer clinical trials.
This study looks at how genetic changes in plasma cell disorders (including MGUS, smoldering myeloma, multiple myeloma, and amyloidosis) affect how patients respond to treatment. By understanding these genetic factors, doctors hope to better predict treatment outcomes and personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a plasma cell disorder such as MGUS, smoldering myeloma, multiple myeloma, or amyloidosis.
- You have had genetic testing (FISH or NGS) done on your bone marrow or blood samples.
- You have been followed for treatment for at least one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This study is collecting blood samples from people with plasma cell disorders to help researchers learn more about these conditions. It may be a good fit if you haven't started treatment yet and are willing to donate samples.
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
This registry collects information from adults with certain plasma-cell conditions like MGUS, smoldering multiple myeloma, multiple myeloma, plasmacytoma, or primary amyloidosis. It may help researchers learn more about these diseases and improve future care.
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.